List of Excipients in Branded Drug NITROSTAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Parke-Davis Div of Pfizer Inc	NITROSTAT	nitroglycerin	0071-0417	CALCIUM STEARATE
Parke-Davis Div of Pfizer Inc	NITROSTAT	nitroglycerin	0071-0417	GLYCERYL MONOSTEARATE
Parke-Davis Div of Pfizer Inc	NITROSTAT	nitroglycerin	0071-0417	LACTOSE MONOHYDRATE
Parke-Davis Div of Pfizer Inc	NITROSTAT	nitroglycerin	0071-0417	SILICON DIOXIDE
Parke-Davis Div of Pfizer Inc	NITROSTAT	nitroglycerin	0071-0417	STARCH, CORN
Henry Schein Inc	NITROSTAT	nitroglycerin tablet	0404-9800	CALCIUM SACCHARATE
Henry Schein Inc	NITROSTAT	nitroglycerin tablet	0404-9800	GLYCERYL MONOSTEARATE

Nitrostat Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Nitrostat is a sublingual nitroglycerin tablet used for the acute relief and prevention of angina pectoris. Its commercial value is tied to rapid tablet disintegration, dose uniformity at very low drug loads, nitroglycerin stability, moisture protection, and patient usability. The core active-ingredient and dosage-form patents are old, leaving the main opportunities in generic substitution, excipient optimization, packaging, line extensions, and differentiated delivery systems.

What is Nitrostat and how is it formulated?

Nitrostat contains nitroglycerin in 0.3 mg, 0.4 mg, and 0.6 mg sublingual tablet strengths. The tablets are placed under the tongue, where nitroglycerin is absorbed through the oral mucosa. The product is intended to provide rapid onset without relying primarily on gastrointestinal absorption or hepatic first-pass metabolism (Pfizer, 2023).

The FDA labeling identifies the inactive ingredients as lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. Strength-specific coloring may also be used depending on the marketed presentation. The formulation is therefore a conventional low-dose immediate-release tablet rather than a polymeric film, spray, capsule, or modified-release dosage form.

Product attribute	Nitrostat profile
Active ingredient	Nitroglycerin
Route	Sublingual
Strengths	0.3 mg, 0.4 mg, 0.6 mg
Dosage form	Sublingual tablet
Primary performance target	Rapid disintegration and transmucosal absorption
Key excipient risks	Moisture sensitivity, lubricant overuse, dose uniformity, mouthfeel
Primary packaging concern	Protection from moisture and loss of nitroglycerin potency
Regulatory pathway for competitors	ANDA or 505(b)(2), depending on product design
Main commercial competitors	Generic nitroglycerin sublingual tablets, nitroglycerin lingual sprays, other short-acting nitrates

What excipients are used in Nitrostat?

The listed Nitrostat excipients support compression, tablet structure, flow, lubrication, and rapid breakup.

Lactose

Lactose acts primarily as a diluent. Because the nitroglycerin dose is measured in fractions of a milligram, the formulation requires a substantial quantity of carrier material to create a tablet with adequate mass and content uniformity.

Lactose creates several strategic considerations:

• Patients with severe milk-protein or lactose-related sensitivities may seek alternatives.
• Lactose can contribute to moisture-management requirements.
• Replacement with mannitol, sorbitol, or a directly compressible co-processed excipient could support a differentiated product.
• A lactose-free version could be positioned for institutional formularies and patients who avoid lactose-containing products.

The practical challenge is maintaining blend uniformity when the active ingredient is present at an extremely low concentration.

Microcrystalline cellulose

Microcrystalline cellulose provides compactibility and tablet strength. It is useful in low-dose tablets because it supports mechanical integrity without requiring high compression forces.

For Nitrostat-type products, excessive compression can delay tablet breakup and slow sublingual absorption. Microcrystalline cellulose selection, particle size, and concentration therefore affect both manufacturability and clinical performance.

Pregelatinized starch

Pregelatinized starch can act as a binder and disintegrant. It helps the tablet hold together during packaging and handling while supporting rapid dispersion after administration.

The starch grade and moisture content must be controlled. Too much binding can produce a hard tablet with slower disintegration. Too much disintegrant can weaken the tablet and increase friability.

Magnesium stearate

Magnesium stearate reduces friction during tablet compression and ejection. Its concentration and blending time are important because hydrophobic lubricant films can slow wetting and disintegration.

A generic manufacturer could investigate lower lubricant levels, shorter lubrication cycles, or alternative lubricants such as sodium stearyl fumarate. Any change would require comparative dissolution, disintegration, friability, assay, content uniformity, stability, and bioequivalence analysis.

What excipient attributes are most important for Nitrostat?

The most important excipient attributes are rapid wetting, low moisture contribution, consistent particle size, low adsorption of nitroglycerin, and reliable content uniformity.

Rapid disintegration

Sublingual tablets must break down quickly in a small volume of saliva. Conventional hardness targets are less important than the balance between handling strength and rapid dispersion.

Relevant formulation variables include:

• Disintegrant type and concentration
• Tablet porosity
• Compression force
• Lubricant level
• Particle-size distribution
• Excipient wettability
• Tablet weight and thickness

A differentiated product could pursue faster disintegration, although a faster in vitro result would not automatically create a clinically meaningful advantage.

Content uniformity at submilligram dose

Nitroglycerin represents a very small portion of total tablet mass. Direct blending can create segregation and potency variability. Commercially viable manufacturing may require a controlled premix, ordered mixing, carrier granulation, or liquid deposition onto an excipient.

The excipient must not absorb or chemically destabilize nitroglycerin during blending, compression, storage, or dispensing. Process controls may be more commercially important than the choice of a single excipient.

Moisture and chemical stability

Nitroglycerin is sensitive to formulation and packaging conditions. Moisture, heat, light, and contact with certain packaging materials can affect potency and shelf life. A formulation with a more hygroscopic excipient may require a stronger container-closure system.

Key development tests include:

• Assay and related substances
• Nitroglycerin migration or loss from the tablet
• Water content
• Dissolution and disintegration after humidity exposure
• Container-closure integrity
• In-use stability after repeated opening
• Stability under accelerated and long-term conditions

What excipient substitutions could create commercial opportunities?

The strongest opportunity is not a simple copy of Nitrostat. It is a product that preserves rapid transmucosal delivery while reducing manufacturing, storage, or patient-use limitations.

Lactose-free sublingual tablets

A lactose-free formulation could replace lactose with mannitol, microcrystalline cellulose, calcium phosphate, or a co-processed filler. Mannitol is particularly attractive because it can provide a cooling mouthfeel and relatively favorable palatability.

Risks include:

• Different tablet hardness and friability
• Greater sensitivity to compression conditions
• Changes in dissolution and wetting
• New stability behavior
• Potential need for a new bioequivalence strategy

A lactose-free claim may have greater commercial value than a minor speed improvement because it is easy for pharmacists and patients to understand.

Mannitol-based fast-disintegrating tablets

Mannitol can support a pleasant mouthfeel and rapid dissolution. A mannitol-based platform could be developed as a direct-compression or orally disintegrating tablet.

The product would need to avoid excessive friability, especially if packaged in multidose bottles. Unit-dose blister packaging could reduce breakage and improve moisture control but would increase packaging cost.

Co-processed excipient systems

Co-processed fillers and disintegrants can improve flow, compressibility, and blend uniformity. They may reduce the number of individual formulation variables and support continuous or high-speed manufacturing.

The commercial benefit is strongest where the manufacturer has a scalable process advantage, such as:

• Lower rejection rates
• Better content uniformity
• Reduced blend segregation
• Shorter manufacturing cycles
• Lower sensitivity to operator-dependent blending

Alternative lubricants

Magnesium stearate is effective but can impair wetting when overused. Sodium stearyl fumarate and other lower-hydrophobicity systems may support faster disintegration.

This is a process-development opportunity rather than a standalone patent strategy. The substitution must be linked to measurable performance, such as reduced disintegration time or improved dissolution after storage.

Taste and mouthfeel optimization

Nitroglycerin tablets can produce an unpleasant or burning sensation. Flavoring and sweetening are difficult because excipients must not interfere with low-dose uniformity, stability, or mucosal absorption.

Potential approaches include:

• Mannitol for cooling sensation
• Low-level sweeteners
• Saliva-compatible flavor systems
• Particle engineering to reduce localized concentration
• Coated excipient particles that dissolve rapidly after placement

Any taste-masking system must preserve the immediate-release profile. A coating that delays dissolution could undermine the product’s intended use.

What packaging strategies protect nitroglycerin products?

Packaging is a major part of the excipient and product strategy. A formulation that is stable in a sealed bottle may lose potency after repeated patient opening.

Multidose bottles

Multidose bottles are familiar and inexpensive. They also create exposure to ambient humidity and repeated opening. Desiccants, low-permeability containers, and controlled headspace can improve stability.

Unit-dose blister packs

Blister packaging can reduce moisture ingress and limit repeated exposure. It may also improve dose portability and reduce uncertainty about how long the product has been open.

Commercial disadvantages include higher packaging cost, more complex filling operations, and possible incompatibility between nitroglycerin and blister components.

Child-resistant and adherence-oriented packaging

A product can be differentiated through:

• Child-resistant unit-dose packaging
• Easy-open senior-friendly systems
• Emergency-use labeling
• Color-coded strengths
• Integrated dose counters
• Carry cases for ambulatory patients

Packaging innovations may be protectable through design, utility, or combination-product claims even when the basic tablet formulation is no longer patentable.

What patents protect Nitrostat and when does Nitrostat lose exclusivity?

The fundamental nitroglycerin compound and conventional sublingual-tablet concepts are long out of patent protection. Nitrostat is therefore exposed to generic competition and formulation substitution.

The relevant intellectual-property categories are:

IP category	Commercial status
Nitroglycerin compound	Historical patents expired
Conventional sublingual tablet	Historical patent protection expired or commercially weak
Basic excipient combination	Likely difficult to enforce without unexpected performance
Packaging	Potentially protectable if novel and nonobvious
Rapid-disintegration platform	Potentially protectable if linked to defined composition and performance
Taste-masking system	Potentially protectable
Manufacturing process	Potentially protectable if it solves uniformity or stability problems
New dosage form, such as spray or film	May support separate patent and regulatory protection
Method of use	Narrow opportunity because angina use is established

Patent value is more likely to arise from a specific composition, manufacturing process, or packaging system than from a broad claim covering nitroglycerin in a sublingual tablet.

What is the Orange Book status of Nitrostat?

Nitrostat has been marketed under an FDA-approved prescription product pathway, and nitroglycerin sublingual tablets have long had generic equivalents. FDA Orange Book review should focus on the current NDA record, active ingredient, dosage form, and listed patents or exclusivity entries associated with the specific applicant.

Because the product is an old small-molecule dosage form, the principal regulatory question is usually abbreviated approval rather than reference-product exclusivity. A generic applicant would generally pursue an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to FDA requirements for sublingual products and any product-specific guidance.

Potential regulatory routes include:

ANDA

An ANDA is the most direct path for a conventional sublingual tablet that matches the reference product in active ingredient, strength, dosage form, route, and performance.

505(b)(2) application

A 505(b)(2) application may be appropriate for a materially different product, such as:

• Sublingual film
• Metered-dose lingual spray
• New excipient system
• Novel packaging and dosing system
• Different strength or administration method

A 505(b)(2) product may obtain labeling or formulation differentiation but can face additional clinical, CMC, and patent-certification requirements.

Which companies are challenging Nitrostat through generic competition?

The generic nitroglycerin market includes multiple manufacturers and private-label suppliers rather than a single dominant challenger. Competition generally occurs through FDA-approved generic sublingual tablets, hospital and pharmacy purchasing contracts, and alternative nitroglycerin delivery systems.

Relevant competitive products include:

• Generic nitroglycerin sublingual tablets
• Nitroglycerin lingual sprays
• Transdermal nitroglycerin patches
• Nitroglycerin ointments
• Other short-acting antianginal products

The competitive threat to Nitrostat is strongest from therapeutically substitutable generic tablets. Spray products compete on convenience and potentially faster administration but usually have different device, formulation, and regulatory requirements.

What generic launch scenarios exist for Nitrostat?

Scenario 1: Conventional tablet substitution

A manufacturer launches a lactose-containing or lactose-free sublingual tablet closely matching Nitrostat. This is the lowest-risk commercial route and likely the fastest path to pharmacy substitution.

Scenario 2: Premium lactose-free tablet

A manufacturer uses mannitol or a co-processed excipient system and markets the product to patients, prescribers, or institutions seeking an alternative to lactose-containing tablets.

Scenario 3: Unit-dose emergency-use product

A manufacturer combines a stable tablet formulation with individually sealed packaging. The product targets ambulatory patients, emergency kits, hospitals, and long-term-care facilities.

Scenario 4: New delivery platform

A 505(b)(2) applicant develops a spray, film, or other rapid-delivery system. The potential price and differentiation are higher, but development costs and regulatory complexity also rise.

How strong is the Nitrostat patent estate?

The core Nitrostat patent estate is commercially weak because nitroglycerin and conventional sublingual-tablet technology are mature. The stronger opportunity lies in new IP covering:

• Excipient ratios
• Nitroglycerin premix architecture
• Low-moisture manufacturing
• Stability-improving packaging
• Rapid-disintegration performance
• Taste and mucosal tolerability
• Device-assisted dosing
• Unit-dose emergency packaging

A defensible patent should connect the composition or process to a measurable result, such as improved potency retention, reduced impurity formation, faster disintegration after humidity exposure, or improved content uniformity.

What are the principal manufacturing and IP barriers?

The main barriers are technical rather than compound-patent based.

Manufacturing risks include:

• Poor low-dose content uniformity
• Nitroglycerin loss during processing
• Adsorption to equipment or packaging
• Segregation of the active premix
• Excessive lubricant coating
• Tablet breakage during handling
• Stability loss after container opening

IP barriers arise when a competitor has protected a specific premix process, moisture-control package, spray device, or fast-disintegrating composition. Freedom-to-operate analysis should cover formulation patents, manufacturing patents, packaging claims, device patents, and regulatory exclusivity records in the United States, European Union, Canada, Japan, and other target markets.

What licensing opportunities exist for Nitrostat alternatives?

Licensing opportunities are most credible in four areas:

1. Fast-disintegrating tablet technology: A platform that improves wetting and tablet breakup without compromising potency.
2. Low-dose blending technology: A process for reproducible nitroglycerin deposition and content uniformity.
3. Moisture-barrier packaging: A container or blister system that extends in-use stability.
4. Novel delivery systems: A lingual spray, film, or metered device with a differentiated administration profile.

An excipient supplier could license a co-processed filler or disintegrant system to a generic manufacturer. A packaging company could license a unit-dose stability system. A specialty pharmaceutical company could license a 505(b)(2) delivery platform to a cardiovascular marketer.

How does Nitrostat compare with other nitroglycerin products?

Product type	Primary advantage	Main limitation	IP opportunity
Sublingual tablet	Low cost, familiar, portable	Moisture and handling sensitivity	Excipient, packaging, process
Lingual spray	Convenient, no tablet disintegration	Device cost and complexity	Device and formulation
Transdermal patch	Extended delivery	Not suitable for rapid rescue	Adhesive and release system
Ointment	Flexible topical administration	Less convenient and slower	Vehicle and dosing applicator
Sublingual film	Potentially rapid and discreet	Manufacturing and stability complexity	Film composition and packaging

Key Takeaways

• Nitrostat is a mature nitroglycerin sublingual tablet with 0.3 mg, 0.4 mg, and 0.6 mg strengths.
• Its listed excipients are lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.
• The main formulation priorities are rapid disintegration, low-dose content uniformity, moisture control, and nitroglycerin stability.
• The core patent position is weak because the active ingredient and conventional dosage form are old.
• The strongest commercial opportunities are lactose-free tablets, mannitol-based formulations, co-processed excipient systems, unit-dose packaging, and alternative delivery platforms.
• Conventional generic tablets are the lowest-risk entry route. Sprays and films offer greater differentiation but may require a 505(b)(2) strategy.
• Packaging and manufacturing processes may provide more valuable IP than the basic excipient combination.
• Regulatory and commercial success will depend on stability, content uniformity, in-use performance, and reliable rapid disintegration.

FAQs About Nitrostat Excipient and Commercial Strategy

Can lactose be removed from Nitrostat without changing the regulatory pathway?

Yes, a lactose-free generic may remain eligible for an ANDA if it demonstrates pharmaceutical equivalence and bioequivalence and satisfies FDA requirements. A materially different performance profile or dosage form could require a 505(b)(2) application.

Is mannitol a suitable replacement for lactose in nitroglycerin sublingual tablets?

Mannitol is a technically credible replacement because it can support direct compression and favorable mouthfeel. The formulation must still demonstrate acceptable stability, content uniformity, disintegration, dissolution, and bioequivalence.

Can a faster-disintegrating Nitrostat formulation obtain new patent protection?

Potentially. Patentability would depend on a novel and nonobvious composition or process, supported by defined performance results. A broad claim to faster disintegration alone would likely be difficult to defend.

Does nitroglycerin packaging create a separate commercial advantage?

Yes. Unit-dose or high-barrier packaging can reduce moisture exposure, improve portability, and support in-use stability. Packaging may also support differentiation where tablet composition is difficult to distinguish.

Is a nitroglycerin sublingual film more attractive than a generic tablet?

A film may offer stronger product differentiation and a higher pricing opportunity, but it carries greater formulation, manufacturing, device, stability, and regulatory risk than a conventional ANDA tablet.

References

1. Pfizer Inc. (2023). Nitrostat (nitroglycerin) sublingual tablets prescribing information. U.S. Food and Drug Administration labeling repository.

2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2022). Abbreviated new drug application submissions: Content and format guidance. FDA.

4. United States Pharmacopeia. (2024). General chapter <701> disintegration. United States Pharmacopeial Convention.

5. United States Pharmacopeia. (2024). General chapter <905> uniformity of dosage units. United States Pharmacopeial Convention.

6. U.S. Food and Drug Administration. (2023). 21 CFR Part 314: Applications for FDA approval to market a new drug. Electronic Code of Federal Regulations.